This Thursday is World Alzheimer’s Day. Whereas the illness straight impacts practically 1,000,000 French individuals, scientific analysis is underway to seek out the treatment for the illness. Biotherapies, marketed in the US, are sources of hope.
This Thursday, September 21, marks World Alzheimer’s Day, which impacts practically 1,000,000 French individuals straight and two million caregivers. This illness of forgetting scares 85% of French individuals. Analysis to discover a therapy is underway. 180 medical trials are happening world wide and 141 molecules are presently being examined.
Biotherapies marketed in the US
For 3 years, biotherapies, already marketed in the US, have been the therapies which have attracted essentially the most consideration from scientific analysis. These antibodies clear up a type of glue, the amyloid protein, gathered within the brains of Alzheimer’s sufferers. If the effectiveness of those biotherapies on reminiscence loss continues to be modest, they elevate new hope: “Lastly, now we have the capability to have an motion on the illness course of. Sadly, it’s not solely the amyloid protein which is at play. For instance, the tau protein, which accumulates in our neurons and results in its destruction, continues to be being examined by biotherapies”, explains Professor Philippe Amouyel, director of the Alzheimer’s Basis.
“Different medication will goal irritation. We’re solely firstly of the method, however will probably be a cocktail of medication that can assist combat the illness,” he continues.
Medicines, preventive measures from the age of 45 and earlier detection… these measures might assist remodel Alzheimer’s illness right into a persistent sickness equivalent to hypertension.